A modeling framework for the economic evaluation of baricitinib in moderate-to-severe rheumatoid arthritis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A modeling framework for the economic evaluation of baricitinib in moderate-to-severe rheumatoid arthritis
Authors
Keywords
-
Journal
Expert Review of Pharmacoeconomics & Outcomes Research
Volume 20, Issue 2, Pages 221-228
Publisher
Informa UK Limited
Online
2020-03-26
DOI
10.1080/14737167.2020.1744435
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prevalence of sustained remission in rheumatoid arthritis: impact of criteria sets and disease duration, a Nationwide Study in Sweden
- (2018) Jon T Einarsson et al. RHEUMATOLOGY
- Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis
- (2018) Evo Alemao et al. PLoS One
- The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis
- (2017) Allan Wailoo et al. HEALTH TECHNOLOGY ASSESSMENT
- Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
- (2017) Roy Fleischmann et al. LANCET
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
- (2017) Peter C. Taylor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
- (2016) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- The challenging interplay between rheumatoid arthritis, ageing and comorbidities
- (2016) Marloes van Onna et al. BMC MUSCULOSKELETAL DISORDERS
- Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation
- (2016) Matt Stevenson et al. HEALTH TECHNOLOGY ASSESSMENT
- Rheumatoid arthritis
- (2016) Josef S Smolen et al. LANCET
- Baricitinib in Patients with Refractory Rheumatoid Arthritis
- (2016) Mark C. Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative
- (2015) C. Roubille et al. JOURNAL OF RHEUMATOLOGY
- AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users
- (2015) P. Vemer et al. PHARMACOECONOMICS
- Economic Evaluation of Tocilizumab Monotherapy Compared to Adalimumab Monotherapy in the Treatment of Severe Active Rheumatoid Arthritis
- (2015) Josh J. Carlson et al. VALUE IN HEALTH
- Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation
- (2014) K Malottki et al. HEALTH TECHNOLOGY ASSESSMENT
- Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry
- (2013) Marloes Vermeer et al. BMC MUSCULOSKELETAL DISORDERS
- Trajectories of functional limitation in early rheumatoid arthritis and their association with mortality
- (2013) Sam Norton et al. RHEUMATOLOGY
- Modeling Good Research Practices—Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1
- (2012) J. Jaime Caro et al. VALUE IN HEALTH
- Tails from the Peak District: Adjusted Limited Dependent Variable Mixture Models of EQ-5D Questionnaire Health State Utility Values
- (2012) Mónica Hernández Alava et al. VALUE IN HEALTH
- Modeling using Discrete Event Simulation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4
- (2012) Jonathan Karnon et al. VALUE IN HEALTH
- Mortality Risk by Functional Status and Health-related Quality of Life in Patients with Rheumatoid Arthritis
- (2011) K. MICHAUD et al. JOURNAL OF RHEUMATOLOGY
- Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2
- (2011) David C. Hoaglin et al. VALUE IN HEALTH
- Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1
- (2011) Jeroen P. Jansen et al. VALUE IN HEALTH
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
- (2010) J. S. Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis
- (2009) Wilbert B. Van den Hout et al. ARTHRITIS AND RHEUMATISM
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now